Compare Gilead Sciences, Inc. (GILD) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs KLA Corp. — how do they compare? Gilead Sciences, Inc. trades at $135.26 (market cap $164.99B), while KLA Corp. trades at $204.15 (market cap $251.82B). The key difference: KLA Corp. is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.47%). Which is the better fit depends on your goals.
| GILD | KLAC | |
|---|---|---|
Market Cap | $164.99B | $251.82B |
Sector | Health | Technology |
52-Week High | $155.80 | $301.71 |
52-Week Low | $110.56 | $84.39 |
Enterprise Value | $188.06B | $253.07B |
Dividend Yield | 2.47% | 0.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
KLA Corporation (KLAC) trades at $198.11, up 2.53% today, with a neutral technical signal despite bullish moving averages. The stock shows strong fundamentals, including a 35.57% net income margin and consistent earnings beats, with Q3 2026 EPS expected at $1.17. Recent corporate actions include a 1:10 stock split and a $2.30 dividend, while cash flow remains positive at $101.78M in 2025. Analyst sentiment is optimistic, with a $246.93 consensus price target implying significant upside.
The outlook for KLAC is positive, driven by AI-driven semiconductor demand and robust profitability, but risks include high valuation multiples and market volatility. Investment opportunities center on growth in advanced packaging, with Wall Street largely bullish; however, investors should monitor competitive pressures and economic cycles that could impact the chip equipment sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
